CVE-2024-54239

CVE-2024-54239 is a critical-severity vulnerability with a CVSS 3.x base score of 9.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-862.

Key facts

Description

Missing Authorization vulnerability in dugudlabs Eyewear prescription form eyewear-prescription-form allows Privilege Escalation.This issue affects Eyewear prescription form: from n/a through <= 4.0.18.

Frequently asked questions

What is CVE-2024-54239?
Missing Authorization vulnerability in dugudlabs Eyewear prescription form eyewear-prescription-form allows Privilege Escalation.This issue affects Eyewear prescription form: from n/a through <= 4.0.18.
How severe is CVE-2024-54239?
CVE-2024-54239 has a CVSS 3.x base score of 9.8, rated critical severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2024-54239 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (55th percentile), an estimate of the probability of exploitation in the next 30 days.
How do I fix CVE-2024-54239?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its critical severity, prioritise patching exposed systems.
Does CVE-2024-54239 have an EU (EUVD) identifier?
Yes. CVE-2024-54239 is tracked in the ENISA EU Vulnerability Database (EUVD) as EUVD-2024-52365.
When was CVE-2024-54239 published?
CVE-2024-54239 was published on 2024-12-13 and last updated on 2026-06-17.

References

Other CWE-862 (Missing Authorization) vulnerabilities

Browse all CWE-862 (Missing Authorization) vulnerabilities →